| Breaking News Pins (Nasdaq: INBS) To Our Radar As It Surges Green Early Wednesday
*Get Our Updates Faster—Tap Here To Receive SMS Alerts*
February 25th Greetings, Friend!
Intelligent Bio Solutions Inc. (Nasdaq: INBS) is surging green early on Wednesday.
Could it have something to do with the massive news INBS dropped this morning? Take a look:
Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry
Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026
Partnership on track to deliver annual production cost savings of more than 40% with expected improvement of approximately 20 percentage points in gross margin annually
Doubled in-house lateral flow test strip production capacity strengthens vertical integration, accelerates R&D, and enables panel expansion
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful receipt and deployment of the first shipment of Intelligent Fingerprinting Drug Screening Readers manufactured under its new strategic manufacturing partnership with Syrma Johari MedTech Ltd. ("Syrma Johari"). The shipment marks a significant step in scaling the Company’s production capacity and validates the operational and financial benefits of the collaboration announced in December 2025.
The readers are now being deployed across key customer verticals, including construction, transportation and logistics, and manufacturing, throughout the U.K. and Europe, supporting growing commercial demand and expanding the Company's installed base ahead of planned entry into the U.S. market, beyond the Forensic Use Only category, later this year. The successful first reader shipment confirms that the Syrma Johari partnership is performing as planned, with readers meeting INBS' quality standards and manufactured in compliance with ISO 13485, MDSAP, and applicable regulatory requirements. With access to manufacturing capacity approximately four times its prior capability, the Company is now positioned to accelerate fulfillment and is on track to deliver annual production cost savings of more than 40%, translating to an expected improvement of approximately 20 percentage points in gross margin annually.
...
"Receiving and deploying our first shipment of readers from Syrma Johari, combined with doubling our in-house lateral flow test strip production capacity, is a transformational step in our ability to scale intelligently and profitably," said Callistus Sequeira, Vice President of Global Quality & Operations at Intelligent Bio Solutions. "We are building a vertically integrated, cost-efficient manufacturing engine that supports margin expansion, accelerates innovation, and positions us to enter the U.S. market with operational strength and the capacity to grow with demand."
...
Read the full article here.
Remember. INBS is a low float profile.
With fewer than 2Mn shares in its float, the potential for heightened volatility could be present on a daily basis (and especially after today's huge news).
Spend a second reviewing my initial (Nasdaq: INBS) report below and consider this profile for your radar. -----
Next up on our radar... Here's a past champ firmly sitting in our crosshairs.
Brought into focus this past summer, it originally popped from an open of $1.28 to a high of $2.25 in the short term.
That run of approximately 74% showed how explosive this under-the-radar Nasdaq profile can be.
Even better, I released recently this idea in December. From an open on the 18th of $6.23, it surged to a high of $24.90 on January 12th for a move of approx. 299% short term.
Now, as key technical indicators hover around SEVERLY oversold levels (as of close Tuesday), a healthy reversal could be approaching on the horizon.
And with this profile's float of fewer than 2Mn shares meaning volatility potential could be significantly heightened on daily basis, this Nasdaq profile now tops our watchlist:
Intelligent Bio Solutions Inc. (Nasdaq: INBS)
Intelligent Bio Solutions Inc. is rapidly emerging as a leader in the medical technology sector, pioneering non-invasive, real-time point-of-care testing solutions that are reshaping how drug screening and diagnostics are conducted worldwide.
With a focus on pain-free, accessible, and accurate testing, the company is positioned at the forefront of a global movement toward more humane and efficient healthcare technologies.
Company Overview
Founded in 2016 and headquartered in New York, Intelligent Bio Solutions Inc. is committed to leveraging advanced technology to develop transformative solutions that improve quality of life.
The company’s mission is to redefine the approach to testing by delivering pain-free, accessible solutions that drive transformative change across healthcare and workplace safety.
Core Technologies and Products
Intelligent Fingerprinting Drug Testing Solution
At the heart of INBS’s innovation is the Intelligent Fingerprinting Drug Testing Solution.
This system utilizes a patented technology that analyzes sweat collected from the fingertips to detect recent drug use-including cann-a-bis, co-caine, o-piate-s, and me-thamp-heta-mine-within the preceding 16–24 hours.
The process is non-invasive, requiring less than a minute for sample collection and delivering results in under ten minutes.
Key advantages include:
- Dignified, Non-Invasive Collection: No need for blood, urine, or saliva samples, reducing discomfort and privacy concerns.
- Rapid Results: Enables timely decision-making in workplace, clinical, and law enforcement settings.
- Portability and Ease of Use: Designed for use in the field, workplaces, and clinics, with minimal training required.
- Hygienic and Cost-Effective: Reduces biohazard risks and maintenance costs, with annual calibration sufficing for ongoing use.
Regulatory Milestones And U.S. Market Entry
A significant milestone was achieved with the submission of the FDA 510(k) pre-market notification for the Intelligent Fingerprinting Drug Screening System in December 2024.
The company’s clinical studies have demonstrated high sensitivity, specificity, and usability, with performance data showing 94.1% accuracy and pharmacokinetic studies confirming the reliability of fingerprint sweat as a matrix for drug detection.
INBS is on track for a planned expansion into the multi-Bn dollar U.S. market in 2026, targeting a region that accounts for approximately 28% of the global drug screening market.
The rising rates of drug positivity in the U.S. workforce-particularly in safety-sensitive industries-underscore the urgent need for effective, rapid, and non-invasive testing solutions like those offered by INBS.
Intellectual Property and Competitive Position
INBS’s technology is protected by a robust intellectual property portfolio, including six U.S. patents covering the lateral flow test strip, sample collection cartridge, cartridge housing, and buffer clip design.
This IP protection strengthens the company’s competitive position as it prepares for broader commercialization and future product development.
Market Opp. And Future Outlook | 
No comments:
Post a Comment